Top Markets
Coin of the day
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
株式のランク #14050
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
株価
$0.88012714
最終同期: 2026-08-31
時価総額
$439.58M
変化(1日)
-4.01%
変化(1年)
1,131.97%
FR
取引 Valerio Therapeutics S.A. (ALVIO)

カテゴリー

Valerio Therapeutics S.A.(ALVIO)の株式分割履歴
Valerio Therapeutics S.A.株(シンボル:ALVIO)は合計で0回の株式分割を実施しました。
最新の株式分割はSep 01, 2026に行われました。
Sep 01, 2026より前に購入されたALVIO株は、現在0ALVIO株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH